38th Annual Society for Immunotherapy of Cancer (SITC) Meeting
Advertisement
Advertisement
CLN-978 was designed for high-affinity binding to CD19 and to enable the killing of low-CD19 expressing blasts.
The strategy is “potentially translatable to all T-cell derived hematological malignancies," according to researchers.
RNA sequencing showed decreased gene expression levels of the NF-κB target genes IL1β and IER3 after emavusertib treatment.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.